ChemDiv is believed to make use of its expertise in drug discovery.
Janssen or Tibotec will fund certain R&D costs of ChemDiv for every research project and ChemDiv will be eligible for certain success milestones.
Under this arrangement, most of the research will be conducted by ChemDiv through its Moscow subsidiary, ChemDiv Research Institute (CDRI).
ChemDiv Research Institute chairman Nikolay Savchuk said collaborative risk sharing under this strategic arrangement is aimed at building up R&D productivity and broadening emerging market access.
"We are delighted to work with Janssen under a flexible entrepreneurial model more common to biotech ventures," Savchuk added.